Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 monotherapy in HER2-expressing gastric and gastroesophageal junction cancer
CTR20190853Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- May 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab in gastric cancer (GC), esophagogastric junction cancer, sponsored by Alphamab Oncology. Started May 2019; status: completed.
02
Drugs
anbenitamab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on CTR20190853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190853.